Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10388535 | 0.82 | POLB (0.49) | SLC6A4SLC6A2 | |
| SCHEMBL19049075 | 0.80 | CCR3 (0.51) | SLC6A4HTR1AEEDSIGMAR1KDM4E | |
| SCHEMBL4281534 | 0.80 | CCR3 (0.49) | SLC6A4HTR1AEEDSIGMAR1KDM4E | |
| SCHEMBL13858982 | 0.80 | SLC6A4 (0.47) | SLC6A4HTR1AEEDSIGMAR1CHRM4 | |
| SCHEMBL19002806 | 0.78 | CCR3 (0.47) | EEDSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL21169224 | 0.77 | CCR3 (0.47) | EEDSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL6132670 | 0.76 | CCR3 (0.45) | EEDROCK2KDM4EALDH1A1 | |
| SCHEMBL13705102 | 0.76 | CCR3 (0.45) | EEDROCK2KDM4EALDH1A1 | |
| SCHEMBL3154073 | 0.74 | EED (0.63) | SLC6A4HTR1AEEDCHRM4DRD2 | |
| SCHEMBL18668 | 0.73 | ALDH1A1 (0.55) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |